Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A Clinical Practice Comparison of Overall Survival, Time-to-Next-Treatment, and Time-to-Treatment-Discontinuation Among CLL/SLL Patients Receiving First-Line Ibrutinib with and without a Del(17p) Mutation

Anthony Mato, MD, Boxiong Tang, MD PhD, Soraya Azmi, MBBS,MPH, Keri Yang, PhD MPH, MS, Jennifer C Stern, PhD, Eric Hedrick, MD, Jane Huang, MD, Jeff P Sharman, MD

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-134119

Published: 2020

Journal Articles

A Systematic Review of the Epidemiology and Economic Burden of Mantle Cell Lymphoma (MCL)

Keri Keri Yang, Eleanor Lucas, BA, Beth Lesher, PharmD, Tony Caver, PhD, Boxiong Tang, MD PhD

Blood (2019) 134 (Supplement_1): 5831.

https://doi.org/10.1182/blood-2019-129677

Published: 2019

Journal Articles

Systematic Literature Review on Global Real-World Treatment Patterns of Mantle Cell Lymphoma (MCL)

Keri Keri Yang, Beth Lesher, PharmD, Eleanor Lucas, BA, Tony Caver, PhD, Boxiong Tang, MD PhD

Blood (2019) 134 (Supplement_1): 5881.

https://doi.org/10.1182/blood-2019-130896

Published: 2019

Journal Articles

Real-World Healthcare Resource Utilization in Patients with Indolent Non-Hodgkin's Lymphoma: Differences between Patients Treated First-Line with Ibrutinib or Bendamustine + Rituximab

Debra Irwin, Lu Zhang, ScD, Kathleen Wilson, MPH, Gerard Hoehn, PhD, Erika Szabo, Boxiong Tang, MD PhD

Blood (2018) 132 (Supplement 1): 3549.

https://doi.org/10.1182/blood-2018-99-113093

Published: 2018

Journal Articles

Assessing the Need for a Biosimilar: A Systematic Literature Review of the Treatment Burden of Rituximab in Hematological Malignancies

Elizabeth James, Holly Trautman, Gerard Hoehn, PhD, Erika Szabo, Boxiong Tang, MD PhD

Blood (2018) 132 (Supplement 1): 5908.

https://doi.org/10.1182/blood-2018-99-110953

Published: 2018

Journal Articles

Real-World Healthcare Resource Utilization in Patients with Chronic Lymphocytic Lymphoma: Differences between Patients Treated with Ibrutinib or Bendamustine + Rituximab

Debra Irwin, Lu Zhang, ScD, Kathleen Wilson, MPH, Gerard Hoehn, PhD, Erika Szabo, Boxiong Tang, MD PhD

Blood (2018) 132 (Supplement 1): 3548.

https://doi.org/10.1182/blood-2018-99-112626

Published: 2018

Journal Articles

Comparative Cost-Efficiency Analysis of Granulocyte Colony-Stimulating Factors for Use in Chemotherapy Patients in the United States

Elizabeth James, Holly Trautman, Erika Szabo, Boxiong Tang, MD PhD

Blood (2017) 130 (Supplement 1): 4667.

https://doi.org/10.1182/blood.V130.Suppl_1.4667.4667

Published: 2017

Journal Articles

Budget Impact Analysis of Switching Chemotherapy Patients Using Granulocyte Colony-Stimulating Factors (G-CSFs) from Pegfilgrastim to Short-Acting G-CSFs in the United States

Elizabeth James, Holly Trautman, Erika Szabo, Boxiong Tang, MD PhD

Blood (2017) 130 (Supplement 1): 4668.

https://doi.org/10.1182/blood.V130.Suppl_1.4668.4668

Published: 2017

Journal Articles

Real-World Characteristics of CLL Patients Receiving Front-Line Therapy, Using the Flatiron Health Database

Boxiong Tang, MD PhD, Erika Szabo, Jifang Zhou, MD, Jerry Wu, Danielle M. Brander, MD

Blood (2017) 130 (Supplement 1): 4671.

https://doi.org/10.1182/blood.V130.Suppl_1.4671.4671

Published: 2017

Journal Articles

Length of Stay for Hospitalized Patients Treated with Ibrutinib or Bendamustine First-Line Therapy for Treatment of Chronic Lymphocytic Leukemia

Debra Irwin, Erika Szabo, Ashutosh Pathak, Boxiong Tang, MD PhD

Blood (2017) 130 (Supplement 1): 5618.

https://doi.org/10.1182/blood.V130.Suppl_1.5618.5618

Published: 2017

Journal Articles

Clinical Outcomes and Cost of Outpatient Community-Based Treatment for Rituximab Refractory Non-Hodgkins Lymphoma (NHL) Patients.

Andrew D. Zelenetz, MD, PhD, Boxiong Tang, MD, PhD, Diana Frame, Luba Nalysnyk, MD, MPH, Catherine Cella, J. Kay Noel, PhD

Blood (2004) 104 (11): 3132.

https://doi.org/10.1182/blood.V104.11.3132.3132

Published: 2004

NARROW

A Clinical Practice Comparison of Overall Survival, Time-to-Next-Treatment, and Time-to-Treatment-Discontinuation Among CLL/SLL Patients Receiving First-Line Ibrutinib with and without a Del(17p) Mutation

A Systematic Review of the Epidemiology and Economic Burden of Mantle Cell Lymphoma (MCL)

Systematic Literature Review on Global Real-World Treatment Patterns of Mantle Cell Lymphoma (MCL)

Real-World Healthcare Resource Utilization in Patients with Indolent Non-Hodgkin's Lymphoma: Differences between Patients Treated First-Line with Ibrutinib or Bendamustine + Rituximab

Assessing the Need for a Biosimilar: A Systematic Literature Review of the Treatment Burden of Rituximab in Hematological Malignancies

Real-World Healthcare Resource Utilization in Patients with Chronic Lymphocytic Lymphoma: Differences between Patients Treated with Ibrutinib or Bendamustine + Rituximab

Comparative Cost-Efficiency Analysis of Granulocyte Colony-Stimulating Factors for Use in Chemotherapy Patients in the United States

Budget Impact Analysis of Switching Chemotherapy Patients Using Granulocyte Colony-Stimulating Factors (G-CSFs) from Pegfilgrastim to Short-Acting G-CSFs in the United States

Real-World Characteristics of CLL Patients Receiving Front-Line Therapy, Using the Flatiron Health Database

Length of Stay for Hospitalized Patients Treated with Ibrutinib or Bendamustine First-Line Therapy for Treatment of Chronic Lymphocytic Leukemia

Clinical Outcomes and Cost of Outpatient Community-Based Treatment for Rituximab Refractory Non-Hodgkins Lymphoma (NHL) Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only